Analysts Set Bausch Health Cos Inc. (NYSE:BHC) Target Price at $8.33

Shares of Bausch Health Cos Inc. (NYSE:BHC) have been given a consensus rating of “Reduce” by the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $8.3333.

A number of brokerages have commented on BHC. Weiss Ratings lowered Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research report on Thursday, February 19th. Barclays reduced their price target on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen cut shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th. Truist Financial boosted their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research report on Wednesday, January 7th. Finally, Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a research note on Monday, January 26th.

Bausch Health Cos Price Performance

BHC opened at $5.39 on Monday. The firm has a market capitalization of $2.00 billion, a P/E ratio of 12.83 and a beta of 0.37. The stock has a fifty day moving average of $6.38 and a 200-day moving average of $6.62. The company has a quick ratio of 1.08, a current ratio of 1.47 and a debt-to-equity ratio of 54.68. Bausch Health Cos has a 12-month low of $4.25 and a 12-month high of $8.69.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings results on Wednesday, February 18th. The company reported $1.08 earnings per share for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.13). The business had revenue of $2.78 billion for the quarter, compared to analysts’ expectations of $2.71 billion. Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%. Equities analysts forecast that Bausch Health Cos will post 4.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Cos

A number of hedge funds have recently modified their holdings of the stock. Caption Management LLC raised its holdings in shares of Bausch Health Cos by 101.1% during the fourth quarter. Caption Management LLC now owns 4,464 shares of the company’s stock worth $31,000 after acquiring an additional 405,789 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Bausch Health Cos by 12,589.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock valued at $34,000 after purchasing an additional 4,910 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Bausch Health Cos by 6,661.3% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after purchasing an additional 5,329 shares in the last quarter. Russell Investments Group Ltd. increased its position in Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after purchasing an additional 3,106 shares during the last quarter. Finally, Camelot Portfolios LLC acquired a new position in Bausch Health Cos in the 4th quarter worth about $59,000. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.